Introduction
Use of animal models to investigate age-dependent diseases in humans typically requires long-term aging. Furthermore, human diseases caused by genetic haploinsufficiency often fail to be modeled at any age in mice. Telomere shortening is thought to contribute to age-related diseases in humans, but this has yet to be demonstrated experimentally in an in vivo model. Many human diseases of homozygosity are recapitulated in mice, though in some cases, telomere shortening in mice homozygous for human disease mutations has revealed disease-related phenotypes (1, 2). It has yet to be demonstrated whether long telomeres in mice are protective against diseases of haploinsufficiency, which are frequently associated with age-related decline. Telomeres in lymphocytes of patients with calcific aortic valve disease (CAVD) are shortened, but whether telomere shortening is a causative factor is unknown (3). The incidence of CAVD increases with age, resulting in over 100,000 valve replacements for aortic valve stenosis (AS) (narrowing) annually in the United States. Fifty percent of individuals with CAVD also have coronary, aortic, or carotid artery calcification and therefore are at increased risk for myocardial infarctions and strokes.
Although CAVD often occurs in those with typical 3-leaflet aortic valves (AVs), a congenital anomaly of the AV in which the valve develops into 2, rather than 3, distinct leaflets (bicuspid aortic valve [BAV] ) markedly raises the risk for CAVD. Approximately one-third of individuals with BAV, which occurs in 1%-2% of the population, will develop CAVD that typically has an earlier onset than usual. Congenital defects of the AV have high phenotypic variability, ranging from asymptomatic disease that becomes apparent later in life upon calcification to neonatal presentation with a thickened AV requiring immediate intervention. The most severe form of AS in the fetus can cause hypoplastic left heart syndrome, and all forms of AS are thought to be genetically linked. Humans with heterozygous NOTCH1 (hN1) mutations, the only known genetic cause of AV disease, exhibit the full spectrum of this phenotypic variability (4-7). However, mice heterozygous for N1 have normal AVs (8) , limiting further investigation in vivo.
Results and Discussion
To examine the role of telomere length in valve disease, we generated successive generations of N1 +/− mice lacking telomerase activity by crossing C57BL/6 mice heterozygous for N1 to those lacking the telomerase RNA component Terc (mTR) (9), as described in Supplemental Figure 1A (supplemental material available online with this article; https://doi.org/10.1172/ JCI90338DS1). Analyzing mice lacking telomerase activity over successive generations (mTR −/− generation 1-3, referred to as mTR G1 -mTR G3 ) allowed the study of N1 +/− mice with progressively shorter telomere lengths to determine the dose-dependent effect of telomere shortening on valve disease.
Diseases caused by gene haploinsufficiency in humans commonly lack a phenotype in mice that are heterozygous for the orthologous factor, impeding the study of complex phenotypes and critically limiting the discovery of therapeutics. Laboratory mice have longer telomeres relative to humans, potentially protecting against age-related disease caused by haploinsufficiency. Here, we demonstrate that telomere shortening in NOTCH1-haploinsufficient mice is sufficient to elicit age-dependent cardiovascular disease involving premature calcification of the aortic valve, a phenotype that closely mimics human disease caused by NOTCH1 haploinsufficiency. Furthermore, progressive telomere shortening correlated with severity of disease, causing cardiac valve and septal disease in the neonate that was similar to the range of valve disease observed within human families. Genes that were dysregulated due to NOTCH1 haploinsufficiency in mice with shortened telomeres were concordant with proosteoblast and proinflammatory gene network alterations in human NOTCH1 heterozygous endothelial cells. These dysregulated genes were enriched for telomere-contacting promoters, suggesting a potential mechanism for telomere-dependent regulation of homeostatic gene expression. These findings reveal a critical role for telomere length in a mouse model of age-dependent human disease and provide an in vivo model in which to test therapeutic candidates targeting the progression of aortic valve disease. Histologic examination of N1 WT mTR G2 mice at 2 months of age did not reveal any evidence of calcification, marked by Alizarin staining ( Figure 1C , n = 16). In contrast, 100% of AVs examined from N1 +/− mTR G2 mice with AS by echocardiography were positive for Alizarin staining ( Figure 1C , n = 4). The calcification was extensive, in many cases encompassing an entire leaflet of the AV and the aortic root and in some cases extending to the aortic vasculature ( Figure 1D ). Calcific regions showed coincident expression of the osteoblast transcriptional regulator RUNX2 (10), indicating an osteogenic switch ( Figure 1E ). 30% of N1 +/− mTR G2 mice with normal echocardiography showed calcification by Alizarin staining by 2 months of age, indicating variable disease progression ( Figure 1C , n = 17). Overall, 43% of N1 +/− mTR G2 mice had AV calcification, with 44% of those having progressed to AS by echocardiography (n = 21).
A subset of N1 +/− mTR G2 mice also showed increased pulmonary valve (PV) peak velocity and peak pressure gradient of blood flow across the valve, indicative of PV stenosis (PS), compared with imately 70% lethality by weaning age (Figure 2A and Supplemental Figure 3A ), and 75% of N1 +/− mTR G3 animals at E18.5 had thickened AV leaflets and/or septal defects, explaining the early lethality (Figure 2 , B and C, and Supplemental Figure 3B ). Because a spectrum of AV disease, ranging from adult onset CAVD to newborn AS, is often observed within families, it is intriguing to consider telomere length as a contributor to phenotypic variability.
Since N1 is thought to stabilize endothelial cells (ECs), preventing their proliferation (13), we investigated whether increased proliferation in the valves of N1 +/− mTR G2 mice might result in further telomere shortening. Phospho-histone H3 (pH3) immunostaining revealed increased proliferation specifically in the valve affected by stenosis in N1-haploinsufficient mice, with no difference in apoptosis by TUNEL staining ( Figure 2D and Supplemental Figure 3 C-F Figure 2D ). Conversely, mice with PS had increased proliferation in the PV compared with N1 WT mTR G2 mice and N1 +/− mTR G2 mice with AS (Supplemental Figure 2F) . Correspondingly, N1 +/− mTR G2 mice with AS showed significantly reduced telomeres PS by echocardiography showed thickened PV leaflets histologically, but lacked calcification (Supplemental Figure 2E, Figure 2F , n = 24). Interestingly, heterozygous mutations in N1 or its ligand JAG1 can also cause human PS or mitral valve stenosis, likely reflective of N1's regulation of endocardial cushions that contribute to cardiac valve development (4, 7, 11, 12) . In total, 31% of N1 +/− mTR G2 mice exhibited an echocardiographic defect in either of the semilunar (aortic or pulmonary) valves (only 1 mouse exhibited defects in both valves), while 55% exhibited a defect by histology at 2 months of age.
Although adult N1 +/− mTR G2 mice developed valve disease, neonatal N1 +/− mTR G2 mice showed no defects by echocardiography, indicating that the valve disease progresses in an age-dependent fashion (P < 0.05 by Barnard's test, neonatal, n = 11; adult, n = 26). While AV defects were observed in the first generation, the severity of AV defects increased between the first and second generations of mice lacking mTR. By the third generation, we observed approx- , n = 8). (C) Representative cross section at E18.5 of N1 WT mTR G3 heart with normal anatomy (top) (n = 13), N1 +/− mTR G3 heart with AV leaflet thickening (middle) (n = 5), or N1 +/− mTR G3 heart with ventricular septal defect (bottom, asterisk) (n = 3).
Arrows indicate AVs. Arrowheads indicate mitral valves. (D) Quantification of pH3 staining for proliferation in adult N1
WT mTR G2 (n = 4) and N1 +/− mTR G2 (AS by echocardiography n = 5, PS by echocardiography n = 5) AVs. *P < 0.05, 1-sided t test, Benjamini-Hochberg correction. (E) Quantification of Q-FISH staining for telomere length in adult N1 WT teins that serve as direct mechanosensors of hemodynamic shear stress in ECs (14) . Given that laminar shear stress protects against atherosclerosis and CAVD (15), age-dependent telomere shortening may place AVs at greater risk by disrupting protective shearinduced GPCR signaling. Shear-induced N1 signaling also activates anticalcific gene networks in ECs (16) (17) (18) , raising the possibility that N1 haploinsufficiency and dysregulated GPCR signaling in telomere-shortened AVs may contribute to the accelerated age-dependent calcification in N1 +/− individuals. Indeed, N1 haploinsufficiency in mice with long telomeres (N1 +/− mTR WT ) downregulated genes involved in cell adhesion, including multiple integrins and actin-binding genes, including Parvb, which has been previously linked to coronary atherosclerosis (19) (Figure 3B ). N1-haploinsufficient mice with shortened telomeres (N1 +/− mTR G2 ) also upregulated Tcf21, which promotes migration of profibrotic cells to atherosclerotic lesions in vivo (20) , and Nrg1, which may contribute to proliferation within thickened To determine the genes dysregulated due to telomere shortening and how N1 haploinsufficiency differentially affected AVs in the context of the baseline telomere length, we performed RNA sequencing on dissected AVs from WT, N1 ) resulted in dysregulation of genes enriched in gene ontology terms related to GPCRs and β receptor response ( Figure 3A and Supplemental Tables 1 and 2 ). GPCRs are one of the few known classes of pro- although in the case of Duchenne muscular dystrophy, the mouse phenotype caused by homozygous mutations in Mdx was only fully manifested upon telomere shortening (1, 2). It will be interesting to determine whether telomere shortening represents a more general approach to modeling human disease in mice, particularly those diseases caused by dose-sensitive mutations. The model described here provides a unique opportunity for dissecting the mechanisms by which telomeres affect age-dependent disease and specifically provides an in vivo system for testing novel therapeutics for AV disease in adults and neonates.
Methods
Experimental details are in Supplemental Methods. All original RNA sequencing data were deposited in the NCBI's Gene Expression Omnibus (GEO GSE83963). Study approval. Protocols were reviewed and approved by the UCSF Institutional Animal Care and Use Committee.
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valve leaflets (21) (Figure 3B ). More broadly, gene dysregulation in N1 +/− mTR G2 mice had significant overlap with genes perturbed in human N1 +/− ECs (16) (17) , in which telomeres are naturally shorter, including those involved in proosteogenic and proinflammatory pathways ( Figure 3C and Supplemental Figure 3I Figure 3J ).
3D chromatin analysis suggests telomeres loop back to promoters in the genome and thereby affect gene expression (24) . We examined the reported sites of telomere contacts genome-wide in human umbilical vein ECs (25) and found that genes dysregulated in telomere-shortened mTR G2 valves were enriched for telomere-contacting promoters compared with all genes ( Figure 3F) valves, were even more enriched for telomere-contacting promoters. Thus, genes dysregulated with decreasing telomere length were increasingly likely to be regulated by promoters associated with telomeres within the 3D chromatin structure in the nucleus, suggesting that disruption of this looping with telomere shortening may result in gene dysregulation responsible for age-related CAVD. This study reveals that telomere shortening erodes the tolerance to haploinsufficiency in age-related disease and that shortening of long telomeres protective in mice can accurately recapitulate a human disease of haploinsufficiency. It is remarkable that despite the broad function of N1 in a myriad of tissues, telomere shortening in N1 heterozygous mice resulted only in cardiovascular disease, precisely recapitulating the clinical phenotype observed in humans with N1 haploinsufficiency. Reduced dosage of N1 led to upregulation of cell cycle genes and increased cell proliferation in the valve, which may shorten telomeres over time past a critical threshold ( Figure 3G) . Calcification of the aortic vasculature, commonly observed in humans with CAVD in an age-dependent manner, was also elicited by telomere shortening. It is interesting that progressive shortening of telomeres not only increased severity of disease, but also mimicked the range of AV disease seen in humans, including neonatal onset. The mechanism by which telomere length affects aging or disease more broadly remains unclear, but the enrichment in genes contacted by telomere looping among those dysregulated in mouse N1 +/− AVs with shortened telomeres suggests a potential mechanism for telomere-dependent regulation of homeostatic gene expression.
While we focused on heterozygosity of N1, the majority of human diseases of haploinsufficiency lack a phenotype in mice heterozygous for the orthologous factor, similar to N1. In contrast, many human diseases of homozygosity are recapitulated in mice, 
